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Chapter 1: General introduction
Iron was believed to have therapeutic value as early as 1,500 BCE though few early uses
for such treatment are now regarded as rational. Modern therapeutic use of orally administered 
iron was introduced by the English physician Thomas Sydenham (1624-1689) in the 17th century
for the treatment of chlorosis (now known as iron deficiency anemia) with “iron tonic” (iron 
filings solubilized by tannins in wine), several years before the presence of iron in blood was
demonstrated (Lemery and Geoffroy, 1713) and before consumption of iron was shown to
increase the iron content of blood (Menghini, 1746). The extensive history of iron in medical
practice has been reviewed elsewhere1,2 . Today iron is recognized as an essential nutrient that is
consumed by human beings in a sufficient amount as part of daily balanced diet. It serves as
cofactors for many enzymes and proteins necessary for numerous biological functions such as
oxygen transport, energy production and synthesis/metabolism of many bio-compounds, all of
which are physiologically indispensable reactions for human3. Despite all these uses, iron can still
be lethal to human if it is present less or more than the required amount. Iron deficiency is the
most severe and widespread nutritional deficiency disorder that continues to affect more than 3.5
billion people of the world population4 and remains the only nutritional deficiency disorder in
industrialized countries5,6 . On the other hand, iron overload causes accumulation of iron in various
tissues and can result in cirrhosis7, neurodegenerative and cardiovascular diseases
(cardiomyopathy, etc.)8,9 that result from formation of reactive oxygen species (ROS) through
Fenton or Haber-Weiss reactions10. These pathological processes are normally prevented through
strict regulation of iron uptake, storage and distribution because there is no regulated route of iron 
excretion.
The average iron level in a healthy human adult is 3 - 4 g. This level is maintained by three
regulated processes in human, iron utilization in bone marrow for the synthesis of red blood cell,
iron storage in liver in the form of ferritin and iron recycling from senescence red blood cells in
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splenic macrophage. Despite that, 1-2 mg of iron is absorbed and loss every day to maintain the
systemic iron balance (Figure 1-1)11. 
Iron Intake 
Duodenum 
~1-2 mg daily 
~200 mg 
Utilization
Bone
marrow 
~150 mg
Storage Plasma
transferrin 
~ 3 mg 
Red blood cell 
(hemoglobin) Senescence red
2,300 mg blood cell 
Macrophage 
500 mg 
Recycling 
Liver 
Iron loss 
• Desquamation
• Menstruation 
~1-2 mg daily 
Figure 1-1. Iron homeostasis in human. Iron balance in human is maintained by strict regulation
of iron intake, utilization, storage and recycling.
The average adult possesses 50 mg per kg of body weight of iron that is obtained from the
diet in two forms, heme (Fe-protoporphyrin IX) and non-heme iron. Heme iron is derived from
the hemoglobin and myoglobin present in red meat. It is more readily absorbed (12-25%
bioavailable) and accounts for 10% of daily dietary iron intake. Non-heme iron refers to various
forms of inorganic iron and is usually derived from plants and iron fortified food. It is poorly
absorbed (<5% available) and accounts for 90% of daily dietary iron intake12. Dietary iron
absorption is important not only to fulfill the intrinsic iron requirement of enterocyte for
controlled regulation of systemic and cellular iron homeostasis, but also to balance the daily loss
of iron. The failure to compensate this loss is the primary cause of iron deficiency anemia. To 
date, the dietary absorption of heme and non-heme iron in human body is far from being
understood due to the lack of structural information on proteins involved in such regulation. In
2
   
          
          
       
          
 
 
           
          
              
          
     
 
           
             
             
               
          
           
         
 
 
 
this thesis, I have discussed the structure-function relationship of three proteins involved in
dietary iron absorption: the product of Heme Responsive Gene (HRG) which is involved in heme
iron absorption, and Duodenal Cytochrome b (Dcytb) and Divalent Metal Transporter-1 (DMT-
1) which are involved in non-heme iron absorption (Figure 1-2).
Lumen 
of duodenum 
Fe2+ 
HCP-1 
HRG-1 
Other? 
H+ 
H+ 
DMT-1 
Ascorbate Monodehydroascorbate 
Biliverdin 
CO2 
HO 
Dcytb 
Fe3+ Fe3+ 
Duodenum
enterocyte 
Blood
vessel 
Fe3+ Fe3+ 
Fe3+Fe3+ 
Fe3+ 
Fe3+ 
Fe3+ 
Fe3+Fe
3+ 
Fe3+ 
Fe3+Fe3+ 
Fe3+ 
Fe3+ 
Fe3+ 
Fe3+ 
Ferritin 
Holo-Tf 
Apo-Tf 
Hephaestin Fpn-1 
PCBP-2 
Figure 1-2. Heme and non-heme iron absorption in duodenal enterocyte. Heme and non-
heme iron from diet are absorbed via different pathways. The imported Fe2+ is bound to PCBP-2,
a Fe2+ chaperone. This is then either stored in the form of ferritin (Fe3+) or transported into the
blood by ferroportin-1 (Fpn-1). Fe2+ in blood is oxidized back to Fe3+ by hephaestin and carried
to other parts of cell in transferrin (Tf) bound form.
In my PhD study, I characterized HRG-4 protein, which is the sole dietary heme transporter
in Caenorhabditis elegans, a heme auxotroph. This is a homolog of HRG-1 protein in human,
which is either expressed in duodenal enterocyte (for the uptake of dietary heme) or lysosomal
membrane of macrophage (for the transport of heme out of phagolysosome after the lysis of
senescence red blood cell). To further understand the human nutritional iron intake, I studied the
molecular mechanism of Dcytb and its possible interaction with DMT-1, which are both
expressed in the brush border membrane of duodenal enterocyte in human.
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Chapter 2: Characterization of a novel heme transporter in animals
2-1 Introduction
Heme, iron (Fe) protoporphyrin IX, covers a large portion of iron in all organisms, and it
is employed as prosthetic group in many essential enzymes that participate in important biological
processes. Heme is an efficient source of iron in diet, that has high bioavailability and easily
absorbed1,2 . Although heme biosynthesis and its regulation have been extensively studied, very
little is known about heme trafficking or heme absorption. Heme readily diffuses through the lipid
bilayers due to the hydrophobicity of the porphyrin ring. However, the exit of heme across the
lipid bilayer is somehow impossible. Because of the hydrophilic property of propionate head 
groups, this hinders the flipping of heme from one leaflet to another3. Therefore, the heme exit
from the membrane is unattainable without the presence of heme transporters in the membrane4. 
In mammals, Heme Carrier Protein-1 (HCP-1) is the first heme transporter that was identified to
be expressed in the apical membrane of duodenal enterocyte. It was isolated from mouse
duodenum, localized to the plasma membrane. The heme uptake was analysed by functional
studies using Xenopus oocytes5. However, recent studies showed that HCP-1 has low-affinity to
heme and it is more involved in folate absorption6. The identity of dietary heme transporter
remained elusive until the discovery of Heme Responsive Gene (HRG) protein.
HRG was first discovered by exploiting the well-defined genetics of Caenorhabditis, a free 
living worm, which is a natural heme auxotroph. This worm lacks of all required genes to 
synthesize heme and solely depends on dietary heme to sustain its growth and development. 
Caenorhabditis elegans Heme Responsive Gene-1 (CeHRG-1) and Caenorhabditis elegans
Heme Responsive Gene-4 (CeHRG-4) were the first heme transporters identified from this
species. These proteins were initially discovered as transmembrane permeases upregulated in 
response to heme deficiency. Both proteins are expressed in the worm intestine with CeHRG-1 
localized within an intracellular vesicular compartment and CeHRG-4 localized to the apical
plasma membrane (Figure 2-1).
5
   
 
          
        
 
          
           
            
           
           
          
             
               
          
 
          
          
C. elegans 
Figure 2-1. Intracellular heme trafficking system in C. elegans. HRG-1 is localized in
endolysosomal membrane, whereas HRG-4 is localized in the apical plasma membrane.
An interesting fact about HRG proteins is that these proteins are broadly conserved in
animals and in human7. In human, HRG-1 expression was first identified in the phagolysosomal
membrane of splenic macrophage, where it transports heme from the phagolysosome to the
cytoplasm during erythrophagocytosis (Figure 2-2). The cytoplasm of erythrocytes is rich in
hemoglobin, a molecule with four iron containing heme groups. During erythrophagocytosis, the
senescence red blood cells (sRBC) are lysed in the acidic environment of the endophagolysosome.
A massive amount of heme is released from this process and exit from phagolysosome via HRG-
1. Heme oxygenase-1 then degrades the heme to release the iron8. Apart from this, HRG-1 is also
hypothesized to be important in the absorption of dietary heme by duodenal enterocyte2.
Fe2+ 
sRBC 
Phagosomal 
maturation 
HO 
Ferroportin 
Fe-oxidase 
Ferritin 
Heme 
Erythrophagocytosis 
HRG-1 
Fe3+ 
Figure 2-2. Heme trafficking in erythrophagocytosis process. Heme released for the
breakdown of senescence red blood cells is transported out of phagolysosome by HRG-1.
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While HRG-1 had been found in diverse organisms including humans, CeHRG-4 appears
only in heme auxotrophs such as roundworms, parasitic helminths, and some protozoan
parasites7,9 . The heme auxotrophs must acquire heme using CeHRG-4 from the environment to
survive. Helminths and protozoan parasites affect more than a quarter of the world’s population10 
and cause tens of billions of dollars of loss in animal and plant production annually11. Therefore,
elucidations of the heme transport mechanism by CeHRG-4 and control of its function will be
expected to be a benchmark for the development of antihelminthics and anti-parasitic drugs. The
study on CeHRG-4 will also provide understanding on human HRG transporters, as these proteins
are broadly conserved. Following that, the objective of this study is to understand the heme
trafficking by CeHRG-4 by using structural and functional studies.
2-2 Material and methods
2-2-1 Protein expression and membrane preparation
An artificially synthesized CeHRG-4 gene that includes C-terminal Strep tag II was cloned
into the pPICZ C vector (Invitrogen) for expression in Pichia pastoris. Cells were grown in
BMGY medium containing 1% (w/v) yeast extract, 2% (w/v) peptone, 0.1 M potassium phosphate
buffer, 1.34% (w/v) yeast nitrogen base, 0.002% (w/v) biotin and 1% (w/v) glycerol.
Overexpression of CeHRG-4 was induced by the addition of 1% methanol. Cells were harvested 
after 30 h of culture growth at 30°C. The harvested cells (~ 80 g) were resuspended in lysis buffer
(~ 200 mL) containing 20 mM Tris-HCl (pH 7.4), 200 mM NaCl, 20% (w/v) glycerol and one
tablet of cOmplete EDTA-free protease inhibitor cocktail (Roche) followed by disruption by bead 
beater using zirconia beads (equal volume with lysis buffer) for 9 min ((1 min disruption + 3 min
interval on ice) – repeat 9 times). Cell debris was removed by centrifugation (9,000 × g for 20
min with an R13A angle rotor and CR22N centrifuge (Hitachi)). The supernatant fluid was
collected and sedimented by ultracentrifugation (40,000 × g for 1 h with a P45AT angle rotor and
7
   
        
   
 
     
 
     
         
           
                
            
           
             
         
       
              
              
          
         
      
        
              
          
          
         
 
 
 
CP80WX ultracentrifuge (Hitachi)) to obtain the membrane fraction. Membrane fraction was then 
homogenized with lysis buffer.
2-2-2 Detergent screening and purification of CeHRG-4 
The solubilization and purification of CeHRG-4 was optimized by detergent screening. List
of the detergents used, and the concentration of detergents used for solubilization and purification
is summarized in Table 2-1. The membrane fraction was diluted in solubilization buffer
containing 20 mM Tris-HCl (pH 8), 150 mM NaCl, 10% (w/v) glycerol, 1 mM EDTA and 0.2 %
(w/v) cholesteryl hemisuccinate (CHS) to a concentration of 5 mg/mL. The diluted membrane
was then solubilized with respective detergent at concentration stated in Table 2-1, for 1 h at 4°C,
with constant stirring. Following ultracentrifugation (40,000 rpm for 1 h), the supernatant fluid
was diluted 10 times by solubilization buffer before loaded onto a column of streptavidin agarose
affinity resin (Strep-tactin; IBA life science). Non-specifically bound material was eluted from
this column with lysis washing buffer containing 20 mM Tris-HCl (pH 8), 150 mM NaCl, 10%
(w/v) glycerol, 1 mM EDTA, 0.01 % (w/v) CHS and respective detergent, and the solubilized
CeHRG-4 was eluted by the same buffer containing 3 mM d-Desthiobiotin (Sigma-Aldrich).
Purification profile was evaluated by SDS-PAGE (Invitrogen). The resulting protein from the
elution fraction was concentrated up to ~500 µL and purified by gel filtration chromatography
(HiLoad 13/30 Superdex 200 pg; GE Healthcare) in buffer containing 20 mM Tris-HCl (pH 7.4),
150 mM NaCl, 10% (w/v) glycerol 0.01 % (w/v) CHS and respective detergent. Based on the
detergent screening, DDM was chosen for final purification for crystallization, using the
purification protocol stated above. The oligomerization state of CeHRG-4 was evaluated by blue
native PAGE using NativePAGE Bis-Tris gel system (Invitrogen).
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Table 2-1: List of detergent used for solubilization and purification
Detergent Detergent name CMC* Solubilization Purification
abbreviation (%) Concentration Concentration
LDAO n-Dodecyl-N,N- 0.023 0.48% 0.07%
dimethylamine-N-
oxide
C8E4 Tetraethylene 0.25 1.3% 0.5%
glycol monoctyl
ether
DM n-Decyl-b-D- 0.087 1% 0.26%
maltopyranoside
DDM n-Dodecyl-b-D- 0.0087 1% 0.05%
maltopyranoside
UDM n-Undecyl-b-D- 0.029 1% 0.087%
maltopyranoside
C12E8 Octaethylene 0.0048 1% 0.014%
monododecyl ether
CHAPS 0.49 1.6% 0.61%
Sodium Cholate 0.60 1.6% 0.8%
*Critical micelle concentration (CMC) is the concentration of detergents above which micelles
are spontaneously formed 
2-2-3 Crystallization of CeHRG-4
Highly purified CeHRG-4 was concentrated and crystallized by vapor diffusion (sitting-
drop) method and incubated at 20 °C and 4 °C. Few crystal hits obtained from crystallization
screening by commercially available screening kits were picked and flash cooled by liquid
nitrogen. These conditions were not optimized further because the crystals were not diffracted by 
X-rays.
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2-2-4 In vivo yeast spot assay 
The pYES-DEST52 (Thermo Fisher Scientific) carrying the CeHRG-4 gene were
transformed into hem1D Saccharomyces cerevisiae mutant. This mutant strain lacks the gene
encoding aminolevulinic acid (ALA) synthase, which is the rate-limiting enzyme in the heme
biosynthesis pathway. Prior to spotting, cells were cultivated in enriched synthetic complete (SC)
medium without histidine, containing 2% w/v raffinose for 18 h to deplete heme. Cells were then 
suspended in water to an A600 of 0.2. 10 µL of 10-fold serial dilutions of each transformant was
spotted onto 2% w/v raffinose SC (-His) plates supplemented with either 0.4% (w/v) glucose
(suppress the protein expression) and 250 µM ALA (positive control), or 0.4% (w/v) galactose
(induce the protein expression) and different concentrations of hemin (1, 3 and 10 µM) or different
concentration of protoporphyrin IX (PPIX) (1, 3 and 10 µM). Plates were incubated at 30 °C for
3 days before imaging.
2-3 Results
2-3-1 Expression and purification of CeHRG-4
Recombinant CeHRG-4 was overexpressed in Pichia pastoris. The expression of CeHRG-4 was
confirmed by western blot with anti-strep tag II antibody (Figure 2-3), and the protein purification
by affinity and gel filtration chromatography were optimized by detergent screening (Figure 2-4 
& 2-5). High yield of purification was observed after affinity chromatography by using DDM,
UDM and C12E8 detergents. However, the oligomerization state was observed to differ drastically
for each detergent from gel filtration chromatography.
10
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Figure 2-3. Western blot analysis of CeHRG-4, expressed in yeast. 25.0 µg protein was loaded
per lane, and expressed protein was detected by anti-strep tag II.
LDAO; 0.07% C8E4; 0.5% DM; 0.26% DDM; 0.05% UDM; 0.087% C12E8; 0.014% 
CHAPS; 0.61% Sodium Cholate; 0.8% 
1. Membrane crude 
2. Solubilized protein Solubilization 
3. Unsolubilized protein 
4. Flowthrough 
Affinity
HRG-4 (~19kDa) 5. Wash fraction
chromatography
6. Elution fraction 
Figure 2-4. SDS-PAGE profile for detergent screening in affinity chromatography. CeHRG-
4 obtained from solubilization and affinity chromatography was analyzed by SDS-PAGE. Better
yield of purified protein was obtained using DDM, UDM, C12E8 and CHAPS, in that order.
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Figure 2-5. Gel filtration profile for CeHRG-4 under various detergents. The number of
oligomers of CeHRG-4 under each detergent was determined by comparing the peak position
with gel filtration standard.
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DDM was chosen as the final choice for solubilization and purification, and CeHRG-4 was
purified by affinity and gel filtration chromatography, in the presence of DDM and CHS (Figure
2-6). Two peaks were observed from the gel filtration profile, peak 1 is the void volume and peak
2 is 8-mer of HRG-4.
Figure 2-6. Protein purification profile. a. Purification chromatogram from gel filtration
chromatography. The red and blue line represent absorbance at A260 nm and A280 nm, respectively b.
10% SDS-PAGE of purified CeHRG-4.
Sample from affinity chromatography and two peak fractions from gel filtration chromatography
were used for blue native page to analyse the oligomerization state of CeHRG-4. Two visible
bands appeared in native page (Figure 2-7). The lower band at ~40 kDa might correspond to the
detergent micelle, whereas the top band at ~146 kDa might correspond to CeHRG-4 8-mer.
Figure 2-7. Blue Native PAGE analysis of CeHRG-4. Lane 1, 2 and 3 corresponds to sample
from gel filtration peak 1 (30 µM), gel filtration peak 2 (10 µM) and affinity chromatography (30
µM), respectively.
13
   
      
 
       
            
           
          
 
            
            
 
 
    
 
     
       
       
            
        
    
        
              
2-3-2 Initial crystallization screening of CeHRG-4
Potential hits in the initial crystallization screening of CeHRG-4 were obtained only in a
few conditions from 384 conditions of commercially available crystal screening kits (Figure 2-8).
The sample in the drop were picked and flash cooled in liquid nitrogen. No diffraction spots were
observed for any of these sample at BL32XU of SPring-8.
Figure 2-8. Initial crystallization screening of CeHRG-4. The sitting drops of CeHRG-4 were
equilibrated by vapour diffusion (0.1 µL protein solution + 0.1 µL precipitant solution) at 20°C.
2-3-3 In vivo yeast spot assay 
Notably, transformants hem1D S. cerevisiae expressed CeHRG-4 expression showed 
positive and significant growth, at increasing concentration of hemin and protoporphyrin (PPIX),
with better growth in hemin than PPIX. On the other hand hem1D S. cerevisiae strain transformed 
with vector showed slight growth only at high concentration of hemin and PPIX (10 µM), with
better growth in PPIX compared to hemin. The accumulation of red pigment was observed in
CeHRG-4 transformed strain at high hemin concentration (10 µM), and no pigmentation was
observed in vector transformed strain (Figure 2-9). The red pigmentation is caused by the
mutation in ade2 gene, that is present in the hem1D genetic background12,13 . This mutant
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accumulate phosphoribosylaminoimidazole, an intermediate in the adenine biosynthesis pathway,
and this turns red in the presence of oxygen14. Therefore, high pigment accumulation in CeHRG-
4 transformed is a sign that oxidative phosphorylation or mitochondrial respiration was restored
in this heme-deficient mutant, by hemin source and not by PPIX source.
POSITIVE CONTROL NEGATIVE CONTROL 
+250 μM ALA -ALA 
ALA 
HRG 
vector 
+0.4% Glucose hem1Δ +0.4% Galactose 
1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 
+1 μM hemin +3 μM hemin +10 μM hemin 
hem1Δ +0.4% Galactose +0.4% Galactose +0.4% Galactose 
HRG 
vector 
1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 
+1 μM PPIX +3 μM PPIX +10 μM PPIX 
hem1Δ +0.4% Galactose +0.4% Galactose +0.4% Galactose
HRG 
vector 
1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 1 10⁻¹ 10⁻² 10⁻³ 10⁻⁴ 
Figure 2-9. In vivo yeast spot assay for CeHRG-4 and vector transformed heme deficient S.
cerevisiae mutant. The hem1D S. cerevisiae mutant strain transformed with the indicated
constructs were spotted in 10-fold serial dilution.
2-4 Discussion
As a heme auxotroph, C. elegans solely depends on dietary heme source for its survival.
CeHRG-4 was identified as the only heme transporter that transports extracellular heme into the
intestinal cytoplasm. Understanding the mechanism of heme trafficking by membrane protein 
transporter at atomic level is an interesting issue that still remains unresolved due to no structural
information available for any heme transporter.
Heme 
PPIX 
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The main aim of this study was to structurally characterize CeHRG-4. Although the protein
was successfully purified, no promising crystals were obtained from crystallization screening. In
membrane protein research, one of the most important step is the choice of best detergent that
maintain the target membrane protein in a functional, folded state in the absence of membrane15. 
This was a big challenge in CeHRG-4 purification and crystallization. Based on the comparison
between gel filtration standard and the gel filtration chromatography profile of CeHRG-4 under
different detergents, the protein was found to acquire various numbers of oligomers, ranging from
dimer to 8-mer, and most of the protein were eluted in the void fraction. Since the actual
oligomerization state of CeHRG-4 is not known, this property could not be used to evaluate the
choice of detergent. Choice of detergent was finally made from the protein yield and detergent
critical micelle concentration (CMC). A larger detergent CMC is not suitable for crystallization
as the detergent micelles will interrupt crystal packing. Following that, DDM was used for
solubilization and purification of CeHRG-4. The crystallization of CeHRG-4 remains a challenge
even with optimized detergent conditions. The success of crystal structure depends on the unique
and tight arrangement of protein molecules in the crystalline liquid. Homogeneity of purified
protein and space between each molecules are important factors that determines this packing.
Both this factors are highly affected in the purified CeHRG-4 due to the presence of detergent
micelle.
An interesting finding from the current study is the hemin and PPIX transport assay using
heme deficient S. cerevisiae mutant. A previous study on CeHRG-4 proposed a mechanistic
model for heme import trafficking route using mutagenesis and functional assay. By using the
topological model of CeHRG-4, they found a few conserved Histidine residues, which are
predicted as heme ligand or heme interacting site, and these residues are shown to be conserved 
among other HRG proteins. H108 is one of main residue, which is placed on the external loop of
the non-cytoplasmic side (Figure 2-10), that probably binds to the heme at the metal centre and
initiate the heme transport9. However, the ability of CeHRG-4 to transport PPIX shows that this
protein possibly identifies heme by the porphyrin ring in addition to the metal centre.
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Figure 2-10: Putative topological model of CeHRG-4 adapted from Yuan et al., 2011. The
shaded residues were predicted as potential heme interacting residues. H108 was known as main
residue involved in triggering the heme transport through heme interaction 
2-5 Conclusion
In summary, the role of CeHRG-4 in heme transport is partly understood from the in vivo
yeast spot assay. CeHRG-4 is also able to transport PPIX in addition to heme. The mechanism of
heme transport and the heme binding or interaction site is still unknown, and further investigation
is required to clearly understand the role of CeHRG-4 in heme transport. With the advancing field
of X-ray crystallography and electron microscopy, the problematic structural determination of
HRG proteins could be tackled in near future.
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Chapter 3 : Structural insights into non-heme iron absorption in human
duodenum
3-1 Introduction
Non-heme iron represents the majority of iron consumed by humans in their diets. It is
highly found in grains such as rice, wheat and oats, in nuts, fruits, vegetables, fortified foods and
in most iron supplements. Moreover, 55-60% of iron found in meat is also non-heme iron. Human 
body absorb heme iron better than non-heme iron. This is one of the reasons why vegetarians are
more at risk to develop iron deficiency anemia. The main cause for this is the unawareness about
the importance and mechanism of non-heme dietary iron absorption.
Non-heme iron primarily occurs in its oxidized, water insoluble ferric form (Fe3+). The
absorption of non-heme iron has long been known with the discovery of Duodenal Cytochrome
b (Dcytb)1 and Divalent Metal Transporter-1 (DMT-1)2. Dcytb is membrane embedded iron-
regulated Fe3+ reductase that was first identified in the duodenal brush border of mice with
systemic iron deficiency1. As DMT-1 is selective for the absorption of iron in its ferrous form
(Fe2+)2, the reduction of Fe3+ to Fe2+ by Dcytb in the duodenum is the key step for effective
intestinal iron absorption (Figure 3-1).
Figure 3-1. Non-heme iron absorption in duodenal enterocyte. Dietary iron is imported into
duodenal enterocyte via DMT-1 following reduction by the transmembrane ferric reductase Dcytb. 
Dcytb DMT-1 
Fe3+ Fe2+ 
Duodenal enterocyte
Gut 
lumen 
Ascorbate 
(Asc) 
Dehydroascorbate 
(DHA) 
e -
The importance of Dcytb in iron homeostasis has been studied for a long time. Notably,
the expression and activity of mucosal Dcytb are closely associated with chronic anemia and 
19
   
            
               
        
           
            
             
      
              
              
          
             
             
             
           
             
             
             
      
           
              
        
        
          
          
         
           
      
hypoxia3. Dcytb utilizes ascorbate in cytoplasm as an electron donor to reduce apical Fe3+. Human 
enteric ferric reductase Dcytb is a member of the cytochrome b561 (Cytb561) protein family, all of
which are ascorbate-dependent oxidoreductases that are homo-dimeric, integral membrane
proteins. Each monomer possesses six transmembrane helices and two heme b groups4,5 . All
members of this family use cytoplasmic ascorbate as an electron donor for the reduction of a
substrate at the non-cytoplasmic side of the enzyme. The two heme b groups mediate intra-
molecular electron-transfer reaction across the membrane.
The absorption of bioactive and water soluble Fe2+ is a challenge for all forms of life and 
left a great impact on evolution. This biological challenge has led to the identification and
functional characterization of many ferric reductases. The most well studied metalloreductase is
FRE family from yeast. FRE reduces siderophore-bound iron and oxidized copper prior to uptake
by yeast metal transporters6,7 . The ferric reductase in plants is known as ferric reductase oxidase
(FRO) protein, which was first identified in Arabidopsis, as a protein that reduces Fe3+-chelates
at the root surface-rhizosphere interface8,9 . Plants also possess a protein from Cytb561 family,
however, the role of plant Cytb561 as Fe3+ reductase has not been fully established due to the
existence of FRO protein as their principal Fe3+ reductase. Compared to yeast and plants, humans
have two classes of ferric reductases, Dcytb from Cytb561 family, and STEAP3 from the STEAP
protein family, which is required for transferrin-dependent iron uptake and expressed as
lysosomal membrane protein10. Dcytb however, is the only iron-regulated ferric reductase that is
required for optimal iron metabolism. It is likely to increase the bioavailability of Fe2+ for the
transport by DMT-1 under iron limited condition in human body.
Following the importance of Dcytb in human iron metabolism, the knowledge for the
molecular mechanisms of the iron recognition, ferrireductase function and electron transfer on
the Dcytb is necessary to understand and eradicate the iron metabolism disorders. However, it has
been hampered by the lack of atomic-level structural information of Dcytb. This work provides
the first crystal structure of Dcytb in ascorbate and metal bound form. Biochemical and
spectroscopic analysis combined with the structure-guided mutagenesis were also performed to 
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gain the functional insights of Dcytb. Since ascorbate is known as a vitamin C cofactor to enhance
dietary iron absorption11,12 , the effect of dietary Fe3+-chelators on Dcytb function was also
investigated. These findings provide insights on how humans absorb non-heme iron at the atomic
levels and another role of ascorbate and dietary iron-chelators for non-heme iron absorption that
facilitates the development of new and effective oral ferrotherapy.
3-2 Material and methods
3-2-1 Expression and purification of Dcytb 
A codon-optimized gene encoding Dcytb that includes a thrombin cleavage site followed 
by a C-terminal hexa-His tag was cloned into the pET-21b(+) vector (Merck Millipore) for
expression in Escherichia coli BL21 Star(DE3) (Invitrogen). Transfected cells were grown in TB
medium containing d-aminolevulinic acid (ALA) (0.5 mM) and ampicillin (50 mg L-1).
Overexpression of Dcytb was induced by isopropyl b-D-thiogalactoside (0.1 mM) when the
culture achieved an OD600 of 1.5-1.7, and cell growth was continued for 18 h at 20°C. The
harvested cells (~80 g) were suspended in phosphate buffered saline (pH 7.0) to a final volume
of 120 mL. DNase I (10 mg/mL), lysozyme (20 mg/mL) and one tablet of cOmplete EDTA-free
protease inhibitor cocktail (Roche) were added to this mixture, followed by disruption with a
French press (Ohtake). Cell debris was removed by centrifugation (7,400 × g for 30 min with an
R13A angle rotor and CR22N centrifuge (Hitachi)). The supernatant fluid was collected and
sedimented by ultracentrifugation (66,000 × g for 1 h with a P45AT angle rotor and CP80WX
ultracentrifuge (Hitachi)) to obtain the membrane fraction. This fraction was then homogenized 
with lysis buffer (Na2HPO4 (50 mM), citric acid (10 mM) and NaCl (150 mM), pH 5.8) and
solubilized in a solution containing sodium deoxycholate (0.5% (w/v)) (Wako Pure Chemical)
and n-dodecyl-b-D-maltopyranoside (DDM) (1.7% (w/v)) for 1 h at 4°C. Following
ultracentrifugation (40,000 rpm for 1 h), the supernatant fluid was loaded onto a column of Ni2+-
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nitrilotriacetate affinity resin (Ni-NTA; Qiagen). Non-specifically bound material was eluted
from this column with lysis buffer containing 10 mM imidazole (pH 5.8) (washing buffer), and
the solubilized Dcytb was eluted by the same buffer containing 500 mM imidazole (pH 5.8). The
hexa-His tag was cleaved by overnight treatment with biotinylated thrombin (Merck Millipore)
(2.5 units per 1 mg of protein) at 20°C, followed by the incubation of this reaction mixture with
streptavidin agarose (Merck Millipore) (32 µL per 1 unit of biotinylated thrombin) for 1 h at 4 °C 
to capture the biotinylated thrombin. The resulting protein solution was loaded into Ni-NTA
column once again, and the His-tag-cleaved Dcytb was eluted with washing buffer. The resulting
Dcytb solution was concentrated to ~4-5 mg/mL by centrifugal ultrafiltration and purified by gel
filtration chromatography (HiLoad 16/600 Superdex 200 pg; GE Healthcare) equilibrated with
MES-Na buffer (50 mM, pH 6.5) containing NaCl (150 mM) and DDM (0.025%). The peak
fractions were collected and concentrated (~15 mg/mL) for crystallization with a centrifugal
ultrafiltration unit (Amicon, Merck Millipore) having a 50 kDa cutoff. The protein concentration
was determined based on UV visible absorbance at A414 nm, where the protein concentration is 1
mg/mL when A414 nm = 10.0.
3-2-2 Crystallization of Dcytb
Purified Dcytb was crystallized by the lipidic cubic phase (LCP) method. This is a rising
approach which allows the crystallization of membrane protein in native like environment13,14 . 
Protein solution (~15 mg/mL) was mixed with monoolein (9.9 MAG; Nu-Chek Prep, Inc) at a 2:3 
ratio (w/w) with a coupled syringe mixer. Samples (50 nL) of protein-laden LCP were dispensed
onto a 96-well sandwich plate (Molecular Dimensions) and overlaid with precipitant solutions
(0.8 µL) with a mosquito LCP device (TTP Labtech). Schematic representation of crystallization
is shown in Figure 3-2. Initial crystallization hits were identified in the presence of 20% (v/v)
Jeffamine ED-2003 and 0.1 M HEPES (pH 6.5). Crystallization conditions were optimized by
screening further with buffer containing a series of Jeffamine concentrations and varying pH.
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Crystals that reached full size (~4-8 µm) within two days at 20°C were harvested from the
mesophase and were flash cooled in liquid nitrogen without additional cryoprotectant. Crystals
of Dcytb with substrate bound were obtained by soaking crystals grown for two weeks at 20°C 
with precipitant solution containing sodium ascorbate (1 M) and ZnSO4 (10 mM) for 30 min and,
finally, flash cooled in liquid nitrogen.
Figure 3-2. Schematic representation of crystallization protocol for Dcytb. a. Preparation of
Dcytb in lipidic cubic phase. b. Protein drop sandwiched in LCP plate after crystallization setup
by mosquito. c. LCP drop with full grown crystals are picked by mesh and flashed cooled in liquid
nitrogen. d. Diffraction data is collected in beamline BL32XU .
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3-2-3 Data collection and refinement
X-ray diffraction data were collected at a wavelength of 1.0 Å (100 K) on beamline
BL32XU at SPring-8 with an EIGER X 9M (Dectris) detector. The ZOO and KAMO15 
(https://github.com/keitaroyam/yamtbx) systems were used for the automated crystal mounting,
loop centering, data collection and data processing. From hundreds of crystals, small-wedge data
(5° per crystal) were collected using 5´5 µm2 beam. All datasets were indexed and integrated by
XDS16 and those indexed with similar latice parameters were scaled and merged with outlier
rejections implemented in KAMO. For Zn2+-ascorbate bound form, hierarchical clustering 
analysis based on unit cell parameters were performed using BLEND17 prior to merging. The best
cluster was selected based on the anomalous difference Fourier peak height at Zn2+. Data
collection statistics are summarized in Table 1. An initial model of Dcytb was obtained by
molecular replacement with Phaser18. Arabidopsis thaliana Cytb561 (PDB code: 4O6Y) was used 
as the search model. The structure was refined with PHENIX19, and model building was carried 
out with Coot20. ANODE21 were used to calculate an anomalous difference Fourier map. The
refinement statistics are summarized in Table 3-1. All structural figures were prepared with the
PyMOL Molecular Graphics System (Version 2.0 Schrödinger, LLC).
3-2-4 Stopped-flow measurements
The rates of the reduction of wild type and variants of Dcytb by ascorbate were determined 
by monitoring the absorbance change at 427 nm with a stopped-flow spectrophotometer
(UNISOKU RSP-1000). For most experiments, concentrations of Dcytb in the syringe of the
stopped-flow instrument were 2 µM in the sample buffer containing HEPES (25 mM, pH 7.0,
with NaCl (150 mM) and DDM (0.05% (w/v)). Protein solutions were degassed and placed under
nitrogen prior to loading into the syringes. For the ligand solution, HEPES buffer (25 mM, pH
7.0, with NaCl (150 mM)) was degassed for 10 min and slowly purged with nitrogen for 30 min.
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This buffer-ligand solution was mixed with a stock solution of 10% (w/v) of DDM (final
concentration: 0.05% (w/v), and 20 mM sodium ascorbate (final concentrations: 2 µM - 5 mM).
The temperature of the sample chamber was maintained at 20 °C with a thermal circulator. Five
measurements of the time course of the reduction of oxidized Dcytb with various concentration
of ascorbate were measured and averaged. The data were fitted by a combination of four
exponential functions using Igor Pro 6 software (Wavemetrics). The rate constants of the fastest
phase k1 (s-1) were plotted against the ascorbate concentrations, and the dissociation constant Ks 
and rate constant kmax in the reaction of ascorbate-dependent heme reduction were obtained by 
equation (1).
Equation (1)
3-2-5 Resonance Raman spectroscopy 
Resonance Raman spectra were recorded with a liquid nitrogen-cooled CCD detector
(Roper Scientific, Spec 10:400B/LN) attached to a single polychromator (Jovin Yvon, SPEX750).
The 441.6 nm line from a He-Cd laser (Kinmon Electric, model CD4805R) was adjusted to 5 mW
at the sample point for excitation. Raman scattering was collected at right angles to the incident
light and focused on the entrance slit (150 µm) of the polychromator. Spectra were obtained at
ambient temperature with a quartz spinning cell (2,000 rpm) having a diameter of 8 mm. Raman 
shifts were calibrated with indene. The Dcytb samples (final concentration 20 µM) with various
concentrations of ZnCl2 (0-10 mM) were prepared in Tris-HCl buffer (50 mM, pH 8.0, containing
NaCl (150 mM) and DDM (0.025%)) and were introduced into the Raman cell sealed with a
rubber septum. The samples were reduced by the addition of dithionite solution (final
concentration 200 µM) under an N2 atmosphere. Electronic absorption spectra were recorded
before and after the Raman measurements to confirm that the samples were not damaged by laser
irradiation.
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Raman spectra were analysed with Igor software (WaveMetrics). After baseline correction,
the spectra were normalized to the intensity of the n7 line at 675 cm-1 . Raman signals around 365-
385 cm-1 were deconvoluted as two Gaussian functions. The dissociation constant (Kd) for Zn2+ 
binding to Dcytb was calculated by fitting the titration data to equation (2), which assumes the
presence of a single binding site for Zn2+.
[Dcytb] + [Zn2+ ] + K
d 
− ([Dcytb] + [Zn2+ ] + K
d 
)2 − 4[Dcytb][Zn2+ ] 
S = S 
0 
+ (S − S 
0
) × 
obs max 2[Dcytb] 
Equation (2)
In this equation, Sobs denotes the estimated area of the Gaussian signal at 381 cm-1 , Smax and S0 
represent the area of the Gaussian peak at 381 cm-1 for Zn-free and Zn-bound samples,
respectively, and [Dcytb] and [Zn2+] denote the total concentrations of Dcytb and Zn2+ in the
sample solution, respectively.
3-2-6 Ferric reductase activity assay
Saccharomyces cerevisiae hem1Dfre1Dfre2D YPH499 strain (hem1::KanMX fre1::LEU2
fre2::HIS3)22 was used for the Fe3+ reductase activity assay. Because yeast gene hem1 encodes
ALA synthase that catalyzes synthesis of ALA, the first step of heme biosynthesis, all growth
media were supplemented with 250 µM ALA to assure adequate heme synthesis for production
of Dcytb. Fe3+ reductase activity exhibited by this transformed yeast mutant was entirely
attributable to expression of the enzyme from the high copy-number plasmid pYES-DEST52
(Thermo Fisher Scientific) carrying the yeast codon-optimized human Dcytb gene. Yeast
transformation and selection were initially performed following growth on appropriate synthetic
complete (SC) medium supplemented with raffinose (2% w/v) and ALA (250 µM). The resulting
cells were suspended and grown in SC medium containing raffinose (2% w/v), ALA (250 µM),
and galactose (0.4% w/v) for induction of Dcytb expression or glucose (0.4% w/v) for suppression
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of Dcytb expression at 30 °C for 24 hours and subjected to Fe3+ activity assay23. Dcytb expression
was evaluated by Western blot analysis with the anti-human Dcytb mouse monoclonal antibody
(homemade, clone 11-2.1). Cells were washed with washing buffer (BSA (2% w/v), Tween 20
(0.1% w/v) in 2×PBS) and then washed twice with reaction buffer (glycerol (5% w/v) and sodium
citrate buffer (50 mM, pH 6.5)). Cells suspended in reaction buffer were distributed into 96-well
plates, and A600nm was measured with a plate reader (SpectraMax 190, Molecular Devices). An
equal volume of assay buffer (reaction buffer containing bathophenanthroline disulfonate (BPS)
(2 mM) and FeCl3 (2 mM)) was added to the cells (T = 0) and incubated in the dark at 30°C, 225
rpm until a red color developed. Absorbance values at 535 and 610 nm were determined, and Fe3+ 
reductase activity (nmol 106 cells-1 hour-1) was calculated with equation (3).
[(A − A ) − (A − A )] × 45 
535nm(sample) 610nm(sample) 535nm(blank) 610nm(blank) 
V × (A − A ) × T 
cells 600nm(sample) 600nm(blank) hour 
Equation (3)
The resulting values of Fe3+ reductase activity were divided by the amount of Dcytb, wild-type
and variants, in each reaction mixture as estimated from the areas of the bands observed on
Western blots with ImageJ software24. To examine the competitive binding assay between Fe3+ 
and Zn2+, 0.00, 0.25, 0.50, 0.75, and 1.00 mM ZnSO4 was added to the assay buffer containing 2
mM FeCl3. To investigate the effects of dietary metal-chelators, the Fe3+ activity assay was
performed in reaction buffer containing glycerol (5% w/v) with HEPES (50 mM, pH 6.8) or Tris
(20 mM, pH8.0) and assay buffer containing 2 mM chelator (sodium citrate, malic acid or oxalic
acid) and 2 mM FeCl3. 
The role of this C-terminal region in Fe3+ reductase activity by in vivo yeast functional
assay. For that, C-terminal truncated (by 60 amino acid residues) codon optimized Dcytb, with
C-terminal hexa-His tag, cloned into pYES-DEST52 vector, was transformed into
Saccharomyces cerevisiae fre1Dfre2D mutant strain. The protein expression from the membrane
crude was then evaluated by Western blot analysis with both anti-human Dcytb mouse
monoclonal antibody (homemade, clone 11-2.1) and anti-His tag antibody.
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Table 3-1. Statistics of X-ray diffraction data collection and refinement
Dcytb (substrate-free) Dcytb (Zn2+ and Asc bound)
Data collection
Beamline (SPring-8) BL32XU BL32XU
Space group C2 C2
Wavelength (Å) 1.0 1.0
Cell dimensions
a, b, c (Å), 64.45, 115.94, 48.43 65.19, 115.57, 48.60 
a, b, g (°) 90.00, 118.45, 90.00 90.00, 118.44, 90.00
Resolution (Å) a 50-2.6 (2.76 – 2.60) 50 – 2.8 (2.97 – 2.80)
Nr of merged crystals 866 600 
Observed reflections 698,003 387,956
Unique reflections 9,644 7,824
Average I/σ(I) a 10.0 (1.1) 8.5 (1.0)
Completeness (%) a 99.3 (99.3) 99.3 (99.7)
Redundancy a 72.4 (68.7) 49.6 (48.8)
CC1/2 (%) 98.6 (68.8) 96.7 (48.1)
Rpim (%) a,b 11.8 (91.2) 22.5 (306.9)
Wilson B-factor (Å2) 26.9 30.9
Refinement
Rwork/Rfree (%) c 19.7/24.5 20.6/25.3
Average B value (Å2) 33.2 42.0
R.m.s.d bond (Å) 0.008 0.009
R.m.s.d angles (°) 1.19 1.25
Ramachandran plot d 
Favored region (%) 96.0 94.6
Outlier regions (%) 0.5 0.5
PDB entry 5ZLE 5ZLG
SBGrid entry 573 574 
a Values in parentheses are for the highest-resolution shell.
b Rpim = Σhkl{1/(n-1)}1/2 Σi|Ii(hkl)-<I(hkl)>| / ΣhklΣiIi(hkl), where n is the multiplicity of reflection
hkl, and <I(hkl)> is the average intensity of i observations.
c Rwork = Σhkl|Fobs(hkl) - Fcalc(hkl)|/ΣhklFobs(hkl), where Fobs and Fcalc are the observed and calculated 
structure factors, respectively. Rfree was calculated with 5% of the reflections.
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3-3 Results
3-3-1 Purification and crystallization of Dcytb 
Recombinant human Dcytb was expressed in Escherichia coli and purified by nickel-
affinity and size exclusion chromatography. The purified protein was stable and mono-disperse.
The purity of Dcytb was evaluated from the RZ value (a Soret peak maximum / A280 nm) and
absorption spectrum. Fractions with RZ value ranging from 2.0-2.7 were pooled together (Figure
3-3).
Figure 3-3. Protein purification profile. a. Purification chromatogram from gel filtration
chromatography. The magenta, blue and red line represent absorbance at A260 nm, A280 nm and A414
nm, respectively b. 10% SDS-PAGE of purified Dcytb. c. UV visible absorption spectra of peak
fractions from gel filtration chromatography.
The electronic absorption spectrum of these pooled fractions showed characteristic of the
spectrum of bis-His coordinated hemoproteins with α- and β-bands observed at 531 and 561 nm,
respectively, for the ferrous form (Figure 3-4). These spectra were essentially identical to those
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previously reported for Dcytb expressed in Sf9 cells25 or E. coli. This recombinant Dcytb was
crystallized by LCP in the absence of substrate (ascorbate or metal ion). Crystals were initially
observed in precipitant solution containing HEPES (pH 6.5) and jeffamine ED-2003 (20% (v/v)).
The maximum growth of crystals ranged from ~4-8 µm (Figure 3-5).
Figure 3-4. Electronic absorption spectra of oxidized and reduced Dcytb. The spectrum of
Dcytb with ferriheme (black) is shown with the spectrum of Dcytb with ferroheme reduced by 
ascorbate (red) and dithionite (blue). The spectrum was measured in MES-Na buffer (50 mM, pH
6.5) containing NaCl (150 mM) and DDM (0.025 %) at room temperature.
LCP drop 
containing
Dcytb and 
monoolein 
Precipitant
solution 
Figure 3-5. Crystals (~4-8 µm) of Dcytb grown in LCP. The LCP crystallization drop consist
of 50 nL protein sample in monoolein cubic phase, surrounded by 800 nL of precipitant solution
containing HEPES (pH 6.5) and jeffamine ED-2003 (20% (v/v)).
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3-3-2 Structural analysis of Dcytb 
Dcytb crystal belongs to the C2 space group and allowed collection of X-ray diffraction 
data to a resolution of 2.6 Å. The structure derived from these data was determined by molecular
replacement on the basis of the structure reported for Arabidopsis thaliana Cytochrome b561 
(AtCytb561)26, which exhibits 36% sequence identity with human Dcytb. Dcytb and AtCytb561 
belong to the cytochrome b561 family, members of which have two heme cofactors per monomer
and act as ascorbate-dependent oxidoreductases4.
The overall structure of human Dcytb is a homodimer in which each monomer possesses
six transmembrane a-helices. The N- and C-termini are located on the cytoplasmic side of the
protein (Figure 3-6a). The Dcytb dimer exhibits crystallographic two-fold symmetry in which
the monomers interact through hydrophobic interactions involving transmembrane helices a5 and
a6 on the cytoplasmic side and helices a4, a5 and a6 on the apical side (Figure 3-7a & b).
Although full-length Dcytb (residues 1-286) was used for crystallization, the atomic model
includes only residues 6–230 because the electron density map for the five N-terminal residues
and the 56 C-terminal residues was disordered, most probably due to its conformational flexibility.
The two heme b groups of each Dcytb monomer are sandwiched between four central
transmembrane helices (a2 to a5) at the apical (or luminal) and cytoplasmic ends of the structure
and are referred to as such. As expected from the electronic absorption spectrum, each heme is
hexacoordinate with H86 and H159 coordinating the iron of the cytoplasmic heme and H50 and
H120 coordinating the apical heme iron (Figure 3-6b). All four of these ligands are highly
conserved in the Cytb561 family. The A-propionate of the cytoplasmic heme forms a salt-bridge
with the side chain of R70 from a2, and the corresponding D-propionate is exposed to the solvent
(Figure 3-6c). The A-propionate of the apical heme forms a hydrogen-bond with the side chains
of E180 from a5 and S118 from a4, and the D-propionate is hydrogen bonded with the side chain
of N115 from a3 (Figure 3-6d). The closest edge-to-edge distance between the two heme groups
within a monomer is 15.5 Å (Figure 3-6b).
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Figure 3-6. Overall structure of human Dcytb. a. Ribbon representation of the Dcytb
homodimer. Each monomer consists of six a-helices (a1 -a6). Both N- and C- termini are located 
on the cytoplasmic side. Each monomer contains two heme b molecules, coordinated by four
highly conserved His residues in a six-coordinate low spin form. b. The edge-to-edge distance
between two heme molecules is 15.5 Å. c. The environment of the heme bound to the cytoplasmic
side of Dcytb is shown. d. The environment of the heme bound to the apical side of Dcytb is
shown.
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Figure 3-7. Homodimeric structure of Dcytb. Residues from each monomer (shown in light
blue and salmon) associate with each other through hydrophobic interactions. a. View from the
cytoplasmic side. Hydrophobic interactions involve residues from a-helices 5 and 6 of each 
monomer. b. View from the apical side. Hydrophobic interactions involve residues froma-helices
4, 5 and 6 of each monomer.
To characterize the structural basis for ascorbate and metal ion binding to Dcytb, we co-
crystallized Dcytb in the presence and absence of ascorbate with and without metal ions (Fe3+, 
Cu2+ and Zn2+) or other compounds such as ferric ammonium citrate and hydroxypyridone. Only
soaking crystals with Zn2+ and ascorbate produced crystals that diffracted X-rays well. Although
Fe3+ and Cu2+ are substrates for Dcytb, these metal ions are spontaneously reduced by ascorbate,
and reduction affects the affinity for the protein or damages the crystal. Zn2+ is not redox active
and is generally known to bind proteins in a manner similar to that of Fe3+ 27-29 . Consequently,
Zn2+ was used as an alternative to Fe3+ in soaking experiments with ascorbate.
The overall structure of Dcytb with Zn2+ and ascorbate bound was determined at 2.8 Å
resolution. This structure exhibited no significant conformational change from the structure of
Dcytb determined in the absence of Zn2+ and ascorbate (rmsd 0.4 Å for all Ca atoms). Close-up 
view at the cytoplasmic and apical side also showed no huge change between apo and holo form,
except for the disordered electron density of F47 (Figure 3-8).
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Figure 3-8. The superposition of apo- and holo- Dcytb. a. The six a-helices of the substrate-
free (green) were superimposed on those of the substrate-bound structure (blue) with an r.m.s.d.
of 0.4 Å for all Ca atoms. b. Close-up view of the superposition from the cytoplasmic side.
Residues that interact with ascorbate are shown as sticks. c. Close-up view of the superposition
from apical side. Residues that coordinate Zn2+-ascorbate are shown as sticks. Of the amino acid
residues in this vicinity, only F47 exhibits any change in orientation upon Zn2+-ascorbate binding.
d. Electron density map of residues around apical side of apo-Dcytb, contoured at 1.5σ. e.
Electron density map of residues around apical side of holo-Dcytb, contoured at 1.5σ. Density of
F47 changed upon Zn2+-ascorbate binding.
Clear electron density for substrate binding was observed at both the cytoplasmic and apical
sides of the protein. The electron density from one ascorbate molecule was observed on the
cytoplasmic surface of Dcytb in proximity to the heme located near the cytoplasmic surface
(Figure 3-9a). Note that in these results, ascorbate cannot be distinguished from the oxidized form,
monodehydroascorbate, so for simplicity we refer only to ascorbate in this report. Consistent with
the properties of ascorbate, the ascorbate-binding pocket on the cytoplasmic side contains three
positively charged residues: the 1-ketone group of ascorbate is hydrogen bonded with R152 from
a5, and the hydroxyl groups at positions-2 and -3 are hydrogen bonded with K83 and K79 from
a3, respectively (Figure 3-9a & b). These three residues are highly conserved in the Cytb561 family.
In addition, the 5-methyl group of the cytoplasmic heme group is within van der Waals distance
of the lactone ring of ascorbate.
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Figure 3-9. Substrate binding on the cytoplasmic side of Dcytb. a. Ascorbate is bound on the
cytoplasmic surface of Dcytb by interacting with three positively charged residues. The omit map
for ascorbate is contoured at 2.5s (orange mesh). b. The positively charged cavity for ascorbate-
binding on the cytoplasmic surface is shown.
The importance of these three residues in the ascorbate binding site was investigated by
stopped-flow kinetics studies of ascorbate reduction of the K79S, K83S and R152E variants
(Figure 3-10 and Table 3-2). The rate of heme reduction was decreased by these substitutions.
Similar results were reported following substitution of the corresponding residues in AtCytb561 26. 
These kinetic results provide evidence that these three residues contribute to efficient electron 
transfer from the cytoplasmic ascorbate to the adjacent heme group of Dcytb. Most probably, the
mutation of one of these three residues would cause slight distortion in the ascorbate binding,
resulting in slower rate of electron transfer from cytoplasmic ascorbate to heme center. The
protein-ascorbate interaction observed in cytoplasmic surface of Dcytb shows some similarity to
that in ascorbate peroxidase (APX)30 in which two positively charged residues (K30 and R172)
interact with ascorbate. However, these two sites differ in a way that a heme propionate and main
chain carbonyl group also interact directly with ascorbate in APX and that the location and
orientation of ascorbate with respect to the heme are different.
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Figure 3-10. Dependence of the initial phase of heme reduction of wild-type and variant
forms of Dcytb on [Ascorbate]. In comparison to the wild-type enzyme, the rates of K79S and 
R152E reduction are nearly halved while the rate of K83S reduction is reduced by ~20%.
Table 3-2. Comparison of dissociation constant and rate constant in the reaction of
ascorbate-dependent heme reduction.
Ks (mM) kmax (s-1)
Wild type 0.68±0.07 330±10 
K79S 0.81±0.05 165±4 
K83S 1.1±0.2 270±20 
R152E 1.1±0.2 170±10 
The metal ion binding site was identified by an anomalous difference Fourier map (Figure
11). Specifically, a strong electron density observed on the apical side of Dcytb near the apical
heme and H108 was assigned to Zn2+. This Zn2+ is coordinated to the Ne2 atom of H108 at a
distance of 2.0 Å. In addition to the density for Zn2+, an additional density was observed very
close to the Zn2+. This extra density appears as a flat shape in the Fo-Fc map that occurs parallel
to F184 and that we attribute to a bound ascorbate (Figure 3-11). This arrangement means that
Zn2+ binding to Dcytb involves coordination to ascorbate. The distances of Zn2+ to the O-2 and
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O-1 atoms of ascorbate are 2.2 Å and 2.8 Å, respectively, and the Ne2(H108)-Zn2+-O-2(ascorbate)
angle is 89º. N107 is not coordinated to Zn2+ but is nearby (3.4 Å). The only other interaction of
ascorbate with the protein occurs through van der Waals contact with F184, which resides 3.5-
4.0 Å from the lactone ring of ascorbate. The weak electron density of the ascorbate
dihydroxyethyl group (C5 and C6 position) probably results from lack of any interaction with the
protein. Although the side chains of Y117, K181 and R187 contribute to the formation of the
large pocket on the apical surface, these residues do not interact directly with ascorbate through
hydrogen-bonding or salt bridge formation (Figure 3-11a & b).
Figure 3-11. Substrate binding on the apical side of Dcytb. a. The Zn2+ binding to H108 and
two hydroxyl groups of ascorbate on the apical surface of Dcytb is shown. The anomalous
difference Fourier map (magenta mesh) calculated from X-ray data collected with 1.0 Å
wavelength is contoured at 3.5s. The omit map for ascorbate (orange mesh) bound to the apical
side is contoured at 4.0s. b. The Zn2+-ascorbate-binding cavity on the apical surface is shown.
3-3-3 Analysis of metal binding by resonance Raman spectroscopy
To characterize Zn2+-binding to H108 of Dcytb further, we studied wild-type Dcytb and
the H108Q variant in the presence and absence of ascorbate and Zn2+ by resonance Raman
spectroscopy (Figure 3-12).
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Figure 3-12. Resonance Raman analysis of Zn2+ binding to reduced Dcytb. The low frequency
region of the resonance Raman spectrum of Dcytb in the absence and presence of ZnCl2 (5 mM)
or ZnCl2 (5 mM) and ascorbate (20 mM) are shown for the wild-type and H108Q variant proteins.
As the heme irons of Dcytb are partially reduced upon laser irradiation, we focused on Zn2+ 
binding to the reduced form, but not the oxidized form, of Dcytb. We collected spectra of Dcytb
in the presence of Na2S2O4 to assure that the heme irons were fully reduced. Upon addition of
ascorbate to either protein, no spectroscopic changes were observed in either the high or low
frequency regions, indicating that ascorbate binding to Dcytb induces no significant structural
changes around the hemes. On the other hand, addition of Zn2+ to wild-type Dcytb in the presence
or absence of ascorbate induced the appearance of a small band at 381 cm-1 in the low frequency 
region. Since the 381 cm-1 band was assigned as a bending vibration of the heme propionate
groups31, the Zn2+ binding could induce the change of the environment of the heme propionate
group. This change in spectrum was not observed following addition of Zn2+ or a mixture of Zn2+ 
and ascorbate to the H108Q variant. H108 is located adjacent to a propionate group of the apical
38
   
               
            
                
             
 
             
            
          
           
            
heme, so the appearance of the 381 cm-1 band in the presence of Zn2+ is consistent with
participation of H108 in the binding of this metal ion as indicated by the crystallographic structure.
By monitoring the increase in intensity of the 381 cm-1 band while titrating Dcytb with Zn2+, the
dissociation constant for Zn2+ binding was estimated to be ~0.5 mM (Figure 3-13 & 3-14).
Figure 3-13. Titration of Dcytb with Zn2+ as monitored by resonance Raman spectroscopy.
The resonance Raman spectra of reduced Dcytb in the presence of various concentrations of Zn2+ 
(red symbols) were obtained with 441.6 nm excitation. The Raman signals around 365~385 cm-1 
were deconvoluted as two Gaussian functions. Black traces represent the fit of these functions to
the data. The Gaussian components at 374 cm-1 (green) and 381 cm-1 (blue) are shown.
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Figure 3-14. The titration of reduced wild-type Dcytb with Zn2+ as monitored by resonance
-1 -1 Raman spectroscopy at 381 cm . The peak areas at 381 cm are plotted as red circles as a
function of [Zn2+]. The black curve represents a fit of the data to equation 2 to provide an estimated
Kd of 0.5 ± 0.1 mM.
We also examined the Fe3+ and Cu2+ titration of fully reduced Dcytb in the presence of
Na2S2O4 but did not observe any change in the low frequency region of the resonance Raman
spectrum. As observed during crystallization experiments, Fe3+ and Cu2+ can be reduced readily 
to Fe2+ and Cu1+, neither of which binds to Dcytb as observed by resonance Raman spectroscopy.
This observation is consistent with the physiological expectation that both Fe2+ and Cu1+ should
dissociate from Dcytb for subsequent transport by DMT-1.
3-3-4 Analysis of electron transfer pathway in Dcytb
The possible pathways for electron transfer from the cytoplasmic ascorbate to iron bound at the
apical surface were explored with the Pathways plugin for VMD32,33 . These calculations suggest
three possible electron transfer pathways as shown in Figure 3-15: First, [cytoplasmic
heme]•Y131• F58 • [apical heme] • Fe3+ (or Cu2+). This pathway includes three through-
space transfers between the two hemes that have distances of 3.6~4.9 Å; Second, a pathway
through a series of covalent and H-bonds along the helix a2 (orange dashed line); and Third, a
pathway along the helix a4 (blue dashed line). These results are compared with those obtained 
from identical calculations for AtCytb561 in Figure 3-15. Despite the differences in structure
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exhibited by these two proteins in the region between the two heme groups of each monomer,
these calculations indicate that the pathways for electron transfer between two heme groups of
each of these two proteins are remarkably similar.
Figure 3-15. Proposed electron transfer routes of Dcytb and AtCytb561. a. In Dcytb, three
possible routes can be proposed based on the current structure: First, through-space electron 
transfer (magenta dashed line) mediated by two aromatic residues (Y131 and F58), which are
aligned within the distance of 4 Å. The F58 is substituted with Leu, Tyr or Met in most of other
members of Cytb561 family, whereas Y131 is conserved or substituted with Phe in other members.
Second, through-bond electron transfer (orange dashed line) mediated by series of amino acid
residues along a-helix 2. Third, through-bond electron transfer (blue dashed line) mediated by 
series of amino acid residues along a-helix 4. b. In AtCytb561, a F129 and L59 mediated route
(magenta dashed line), a route involving covalent and H-bonds along a-helix 2 (orange dashed 
line), and a route along a-helix 4 (blue dashed line) were suggested. A water mediated route
(through space) has also been proposed for AtCytb561 by Lu et al.20, although we could not
reproduce it. The binding of water to N63 of AtCytb561 family because N63 is diverse. Indeed, this
position corresponds to Q62 in Dcytb, a substitution that results in no space for water.
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3-3-5 Ferric reductase activity of Dcytb
As shown above (Figure 3-11), H108, Y117, F184 and N107 contribute to the environment
in the region of metal ion and ascorbate binding. To evaluate the functional roles of these residues,
site-directed mutants of human Dcytb were expressed in a yeast strain (Saccharomyces cerevisiae
fre1Dfre2D) that lacks the endogenous plasma membrane Fe3+ reductases, Fre1 and Fre2.
Expression of wild-type human Dcytb on the plasma membrane of this yeast mutant rescues the
growth of this yeast by providing Fe3+ reduction required for nutritional iron absorption, that is
normally provided by Fre1 and Fre2. In this system, electrons for Fe3+ reduction are supplied by
cytoplasmic ascorbate produced by yeast ascorbate biosynthesis34.
With this growth assay, we first examined the effect of Zn2+ binding on the Fe3+ reductase
activity of wild-type and variant forms of Dcytb (pH 6.5, sodium citrate buffer (50 mM), 5% w/v
glycerol, conditions similar to those in the duodenum35). As [Zn2+] was increased to 1.0 mM,
ferric reductase activity of wild-type Dcytb decreased by about 43% (Figure 3-16a), consistent
with Zn2+ binding to the enzyme competitively with Fe3+.
The functional roles of specific residues were studied next by evaluating the activities of
several Dcytb variants (Figure 3-16b). The H108A and H108Q variants exhibited the lowest Fe3+
reductase activities (20 and 25%, respectively) of those studied. These results are consistent with
the proposal that H108 is a ligand for the binding of Fe3+ as well as Zn2+. Although N107 is not a
Zn2+ ligand, the amide nitrogen is just 3.7 Å from the bound metal ion, so presumably the site for
binding of the Fe3+-ascorbate complex in the structure of the N107F variant is perturbed 
sufficiently to accounts for the 35% activity resulting from this substitution. Interestingly, even
though Y117 is ~6.6 Å from the bound Zn2+, the Y117A and Y117S variants exhibited ~35% and
40% of the wild-type activity. Considering the relative proximity of Y117 to the adjacent
ascorbate, it seems likely that the decreased activities of these variants results from perturbation
of ascorbate binding, which would, in turn, affect binding of Fe3+. A similar mechanism
presumably accounts for the decreased activity exhibited by the F184A variant (~35% of wild-
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type activity). Finally, the proposal that F58 and Y131 participate in the electron transfer pathway 
between the cytoplasmic and apical heme groups is consistent with the observation that the
activities of the F58L and Y131L variants were less than 50% of wild-type Dcytb.
Ferric iron is presented to Dcytb in the duodenum in a variety of chelated forms because
many potential soluble ligands for iron occur in this environment and in nutritional sources of
iron. The relatively accessible binding sites for iron and ascorbate on the apical surface of Dcytb
appear to be compatible with this multiplicity of substrate forms (Figure 3-10), but the influence
of likely iron ligands on Dcytb activity is unknown. To investigate this issue, the effect of soluble
chelators on the Fe3+ reductase activity of Dcytb was evaluated by the individual supplementation
of the yeast assay mixture with a variety of putative dietary chelating agents (Figure 3-16c).
Citrate, which was used as a buffer in the kinetics experiments above, is a known dietary chelator
that supports iron uptake from the gut36. As an excess of citrate may reasonably be expected to 
occupy the relatively accessible binding site for Fe3+ and ascorbate, the effect of soluble chelators
on Fe3+ reduction was evaluated in non-chelating buffers. In addition, because the pH of digesting
nutrients changes from acidic to basic with passage from the stomach to the duodenum35, we
studied Fe3+ reduction by Dcytb under acidic (MES, pH 6.5) and basic (TrisHCl, pH 8.0)
conditions (Figure 3-16c). These studies revealed that at acidic pH, the effect of added ligands on
reductase activity was oxalate > citrate > no chelator > glucose~fructose > malate while at basic
pH, this order was changed to citrate~oxalate > malate > no chelator~glucose~fructose. Notably,
the ability of citrate, malate, and oxalate to accelerate Fe3+ reduction by Dcytb is far greater at
alkaline pH than at acidic pH.
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Figure 3-16. Ferric reductase activity of Dcytb. The values indicated are means ± S.D. of data
from duplicate sets of samples analyzed in triplicate. The “Control” means that the Dcytb 
expression was suppressed in the transformant of wild-type dcytb cDNA-inserted vector, and the
“Vector” shows that the expression vector (no insertion of dcytb gene) was transformed and
performed same culture with wild-type and other variants. Dot-plot (empty circle) shows the data
distribution. a. Competitive binding between Fe3+ and Zn2+ in wild-type Dcytb. The value of 0
mM (~220 nmol 106 cells-1 hour-1) was set to 100% and the relative activity was obtained for
increasing Zn2+ concentration. b. Fe3+ reductase activities of the structure-guided mutants of
Dcytb. Western blot of whole cell lysate of Dcytb-expressed yeasts (1.0 µg protein per lane)
shown in the bottom. c. Effect of dietary metal-chelators on Fe3+ reductase activity in wild-type
Dcytb. The effect of chelators was tested in MES buffer (pH 6.5) and Tris-HCl buffer (pH 8.0).
The activity without chelator for MES buffer (~195 nmol 106 cells-1 hour-1) and Tris-HCl buffer
(~65 nmol 106 cells-1 hour-1) was set to 100%, and the relative activity with chelators was
calculated for respective buffers.
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3-4 Discussion
Human ferric reductase Dcytb is an essential enzyme for enteric iron absorption and a member
of Cytb561 protein family, which utilizes cytoplasmic Asc as electron donor for the reduction of a
substrate in non-cytoplasmic side, in which two heme b molecules mediate intra-molecular
Fe3+electron-transfer reaction across the membrane. The substrate is either or
monodehydroascorbate (MDA), depending on their subcellular localization. The principal
substrate of the enteric enzyme Dcytb is Fe3+ while that of the adrenal and plant enzymes is
monodehydroascorbate. The adrenal enzyme resides in chromaffin granules (CGcytb) and
reduces intra-vesicular monodehydroascorbate for regeneration of ascorbate that is used in the
biosynthesis of the neurotransmitter norepinephrine37. Nevertheless, the CGcytb and the
lysosomal enzyme (Lcytb) have also been shown to be capable of catalyzing Fe3+ reduction by
ascorbate38. The role of Cytb561 in the Asc regeneration is well described in a most recently
reported crystal structure of plant Cytb561 from Arabidopsis thaliana (AtCytb561)26 . This report
was the first Cytb561 family member that has been structurally characterized. This structure
provided potential binding sites for Asc and MDA, which may potentiate its enzymatic activity.
The structural comparison between human Dcytb and plant AtCytb561 could provide valuable
insights into the mechanism of the Fe3+ reduction by Dcytb.
3-4-1 Sequence alignment of Dcytb 
The sequence of the human Dcytb core structure (residues 6-230) shares 36% identity and 52%
similarity with that of the plant enzyme AtCytb561 (residues 9 to 220). Comparison of these two
structures reveals that the six a helices (163 Ca atom pairs) are superimposable with a rmsd of
0.6 Å despite the conformational differences observed in the loop regions that connect the α
helices. Moreover, the relative orientations of monomers within these two dimers differ by only
5º. The overall structure is well conserved among all Cytb561 family members. One significant
difference in the sequence of Dcytb relative to other members of this family is the presence of an
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additional 56 residue C-terminal region that is absent from the AtCytb561 MDA reductase. This
region is located on the cytoplasmic side of the protein and is disordered in the structure of Dcytb
reported here.
Three human proteins belonging to the Cytb561 family, Dcytb (duodenal brush border
membrane), Lcytb (late endosomal-lysosomal membrane), and CGcytb (chromaffin granule),
differ in the length of this C-terminal region (Figure 3-17).
Figure 3-17. Sequence alignment of Dcytb with AtCytb561 and other human members of
Cytb561 family. The four sequences shown here are duodenal Cytb (Dcytb), late-endosomal Cytb
(Lcytb), chromaffin granule Cytb (CGcytb) from Homo sapiens, and Cytb561 from Arabidopsis
thaliana (AtCytb561). Residues conserved in all four sequences are highlighted in red. Dcytb has
a C-terminal sequence that is longer than all other members of this family.
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This solitary difference might be the key to the difference in function and localization of various
Cytb561. Considering that Dcytb and Lcytb act as Fe3+ reductases while CGcytb acts as an MDA
reductase, this C-terminal region may be related to the subcellular locations of the enzymes or to
their physiological functions. The extra-long C-terminal peptide is conserved only in Dcytb of
human and mouse39, both of which are expressed in duodenal brush border membrane and
function as ferric reductase. Indeed, a study reported the role of C-terminal sequence in mediating
the localization of human Lcytb. They found (DE)XXXL(LI)-type signal peptide, placed at 23
amino acids away from the C-terminal end, that targets the protein to the late endosome lysosomal
membrane40. Further studies are required to evaluate the functional role of the C-terminal region
of Dcytb. 
3-4-2 Structural comparison between Dcytb and AtCytb561 
The structural environments of the two heme groups of Dcytb, i.e., coordination of His
residues to the irons and interaction with surroundings, are nearly identical to those of the heme
groups occurring in AtCytb561 in terms of bis-histidyl coordination and interactions with
surrounding residues. This is a common structural feature in the Cytb561 family. On the other
hand, the structure of the protein intervening between the two heme groups that is expected to
participate in intramolecular electron transfer differs significantly between Dcytb and AtCytb561. 
For both proteins, the shortest distance between the two heme centers is 15.5 Å. Inspection of the
AtCytb561 structure led Lu and co-workers to propose involvement of a water molecule and F129
(located 3.5 and 3.6 Å from the cytoplasmic heme, respectively) (Figure 3-15b). Lu and co-
workers suggested that the configuration of this water and the phenyl ring of F129 is suitable for
electron transfer tunneling from the cytoplasmic heme to the non-cytoplasmic heme26. In addition
to this through-space route, a through-bond route involving residues of transmembrane helix-2 
was also suggested for AtCytb561 from computational analysis. However, no experimental
investigation of the mechanism of electron transfer between the heme groups of AtCytb561 has
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been undertaken26. In the case of Dcytb, putative electron transfer routes can be identified through
main chain NH--OC interactions from the cytoplasmic heme ligand through six residues along
helix α2 or α4, and, ultimately, the apical heme ligand (Figure 3-15a). Notably, the putative
through-space pathway differs between Dcytb and AtCytb561 in that (a) F129 of AtCytb561 
corresponds to Y131 in Dcytb, (b) no water molecule occurs in this pathway for Dcytb, and (c)
the phenyl group of Dcytb residue F58 resides between Y131 and the heme while L59 occupies
this position in AtCytb561 (Fig. 4). Consequently, Dcytb residues F58 and Y131 could promote
electron tunneling over a reasonable distance (3.6 to 4.9 Å) (Figure 3-15a). This is consistent with
the in vivo Fe3+ reductase assay analysis of intramolecular electron transfer route of Dcytb variants
with substitutions at these positions (Figure 3-16b). The functional analysis revealed that these
two residues are involved in Fe3+ reduction by mediating electron transfer. However, half of the
activity still remains in these mutants, suggesting that in the absence of through space electron 
transfer, Dcytb can still mediate Fe3+ reduction by through bond electron transfer. Which of these
two routes is highly favorable has been considerable debate within the electron transfer modeling
community. A research group lead by David N. Beratan reported an interesting idea about how
electrons travel through proteins. Generally, electrons take the most common route to travel
through series of covalent and hydrogen bonds, but sometimes the electron may leak from one
chemical bond to a tunneling open space, strongly depending on the protein structure and external
factors that causes structural change41 . 
Comparison of the structures of Dcytb and AtCytb561 also reveals that the apical surface of
Dcytb is far more negatively charged than that of the corresponding region of the plant enzyme.
This characteristic is attributable to the presence of high number of negatively charged amino
acid residues in Dcytb, which are D188 (N186), E36 (G35), D41 (D42), E106 (K104), and E197
(E195) (the corresponding residues of the AtCytb561 enzyme are indicated in parentheses). This
surface may assist in directing Fe3+ complexes toward the active site of the reductase to promote
reaction.
48
   
          
        
              
              
               
         
          
             
           
              
          
           
         
            
                
            
          
             
          
      
 
The binding sites for ascorbate on the cytoplasmic sides of Dcytb and AtCytb561 are 
identical and are defined by the conserved residues K79 (77), K83 (81) and R152 (150) (Figure
3-18a & b). This structural and functional conservation is not surprising as all members of the
Cytb561 family employ ascorbate as a cytoplasmic electron donor. On the other hand, the ascorbate
binding sites at the apical surface of the protein differ between Dcytb and AtCytb561 in a manner
that presumably reflects the differing structural requirements for Fe3+ reduction and
monodehydroascorbate reduction (Figure 3-18c &d). The identification of the Zn2+ binding site
on Dcytb that is located adjacent to the apical binding site for ascorbate provides structural
evidence for Cytb561 involvement in metal ion reduction. The cooperative binding of ascorbate
and Zn2+ to the apical substrate binding site in the Dcytb structure reveals key mechanistic insight
into Dcytb function. Other Cytb561 family members like AtCytb561, are capable of reducing 
monodehydroascorbate to ascorbate at the expense of ascorbate, which binds to the cytoplasmic
substrate binding site, to provide electron to monodehydroascorbate on the apical side. Dcytb
possesses an ascorbate binding site at the cytoplasmic surface of the protein as do other members
of the Cytb561 family, but it also possesses an apical binding site for ascorbate that integrates a
binding site for the Fe3+ substrate that could lead to formation of monodehydroascorbate upon
reduction of Fe3+ to Fe2+. The resulting monodehydroascorbate could then be reduced back to
ascorbate by Dcytb. This mechanism suggests that Dcytb not only reduces Fe3+ but also
regenerates ascorbate from monodehydroascorbate on the apical binding site using electrons
provided by ascorbate at the cytoplasmic binding site.
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Figure 3-18. Comparison of the cytoplasmic and apical substrate-binding sites of Dcytb and
AtCytb561. a. Ascorbate is bound to the cytoplasmic side of Dcytb by interaction with three
conserved residues (K79, K83 and R152). F142 interacts with ascorbate by van der Waals contact.
b. Similarly, ascorbate is bound to the cytoplasmic side of AtCytb561 by three conserved cationic
residues, and Y140 replaces F142 of Dcytb. c. Zn2+-ascorbate is bound to the pocket on the apical
side of Dcytb. Zn2+ is coordinated by H108 and two-hydroxyl groups of ascorbate. H108 is
conserved in all members of Cytb561. Ascorbate is in van der Waals contact with F184. The
dihydroxyethyl moiety of ascorbate is free from interaction with the protein. d. Ascorbate is
bound to the same site on the non-cytoplasmic side of AtCytb561. Ascorbate is in van der Waals
contact with H106 and F182 and forms H-bonds with Y115 and N186.
H108, Y117, and N107 are all identified by the structure of Dcytb as participating directly 
or indirectly in the binding of Zn2+ and, by implication, in the binding of Fe3+. H108 plays a
functionally conserved role in ascorbate binding at the apical surface of both Dcytb and AtCytb561 
50
   
                  
                  
             
           
             
            
           
            
           
             
             
         
 
 
            
           
            
       
       
             
                  
               
               
 
 
              
           
          
and, in providing a ligand for Zn2+ binding, plays a direct role in the binding of this metal ion.
Y117 is too distant (6.6 Å) from Zn2+ to serve as a ligand, and it is just beyond hydrogen-bonding
distance from two ascorbate hydroxyl groups (4.7 Å). But the high affinity of a tyrosine phenolate
for Fe3+ and the possible contribution of this residue to optimal orientation of bound ascorbate
raise the possibility that Y117 might influence the Fe3+ reductase activity of this enzyme. Finally,
the replacement of F105 in AtCytb561 by N107 in Dcytb appears to create an open space for metal
ion binding (Figure 3-18c & d). This is supported by Fe3+ reductase assay as shown in Figure 3-
15b, where the Fe3+ reductase activity was significantly reduced by N107F mutant. Also, the Fe3+ 
reductase activity was more reduced when N107 was mutated by a larger phenylalanine residue,
compared to the mutation by a smaller alanine residue. Superposition of the Dcytb and AtCytb561 
structures (Figure 3-19) suggests that the loop region between α5 and α6 also contributes to
creation of this open space, which is of sufficient size to accommodate metal-chelator complex 
binding.
Figure 3-19. Comparison of the binding pockets on the apical surfaces of Dcytb and 
AtCytb561. a. Superposition of Dcytb and AtCytb561. The α3 helix is bent in the middle to
accommodate binding of Zn2+ and ascorbate. The loop connecting α5–α6 contributes to this
binding pocket and exhibits significant conformational difference between two proteins. Dcytb
(A-chain (blue), B-chain (red)) and AtCytb561 (A-chain (gray), B-chain (orange)) are colored as
indicated. The A-chains of the two proteins were superimposed for calculations. Space filling
models are shown for Zn2+ and ascorbate bound to Dcytb. The α2 helices of the A-chains of both
proteins are excluded from this view for clarity. b. The binding pocket of Dcytb is wide and open.
This view is same as shown in a. c. Ascorbate in the binding pocket of AtCytb561 is more buried.
Another significant finding in the present study is that ascorbate, citrate, and some organic
acids can assist metal-binding to the apical side of Dcytb as Fe3+-chelators. Fe3+-chelate is a 
common substrate for all known Fe3+ reductases (FRE and FRO proteins) reported so far.
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However, the importance of this information has been overlooked due to the absence of
supporting evidence. The present Dcytb structure is the first to show the metal-chelator complex
binding and emphasize the need of chelator for stable binding conformation of metal. The
solubility and oxidization state of non-heme iron are highly affected by physiological pH. Both
Fe3+ and Fe2+ are soluble at the low pH present in the stomach, but as pH increases upon passage
into the duodenum, precipitates form unless iron is bound by soluble iron chelators42 . Our
functional assay with some dietary metal-chelators revealed that citric acid, malic acid, and oxalic
acid promote Fe3+ reduction by Dcytb at duodenal pH. Notably, although oxalate is a known
inhibitor of iron uptake43 , it enhanced Fe3+ reduction by Dcytb at both acidic and basic pH, so the
inhibitory effect of oxalate on iron absorption is not the result of its effect on Fe3+ reduction.
Interestingly, sugars such as glucose and fructose, which are found in oral iron supplements, have
little or no effect on Dcytb activity even though they are known to potentiate iron uptake44,45 . 
These results support the conclusion that the Fe3+ binding site of Dcytb is readily accessible to
interaction with Fe3+-chelator complexes. The pH dependent need of Fe3+-chelator can also be
observed by a notable difference between Dcytb and Lcytb, both of which are classified as Fe3+-
reductase. From the structure and functional analysis, it is known that N107 plays a crucial role
in provide larger space for Fe3+-chelator complex binding. However, this residue is replaced by
phenylalanine in Lcytb, similar to AtCytb561. Since Lcytb is expressed in lysosome, and the
lysosomal pH is highly acidic, the Fe3+ remains soluble and therefore does not require chelator.
3-5 Conclusion
In summary, iron deficiency continues to be a significant cause of malnutrition in both developing
and industrialized nations, in part because intestinal absorption of dietary iron is relatively
inefficient. The current study provides structural insight into the function of one of the two
duodenal proteins that are required for the uptake of dietary non-heme iron. It is also the first
crystal structure that provide the metal binding information for a Cytb561 family member, which
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differentiate their function as Fe3+-chelate reductase or monodehydroascorbate reductase. In 
combination with the current biochemical studies, this work also provides structural insight into
how ascorbate enhances iron uptake and how several potential iron ligands found in various foods
promote or inhibit iron uptake. Understanding the importance and interaction between Fe3+-
chelator and Dcytb could be useful in the development of new and effective therapeutic agents to 
promote iron uptake. Ultimately, knowledge of the structure of Dcytb should enable development
of new, structure-based strategies for promoting the reduction of dietary iron and thereby 
enhancing the bioavailability of this essential nutrient.
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Chapter 4 : The role of Dcytb and DMT-1 in regulating non-heme iron
absorption
4-1 Introduction
DMT-1, also known as Natural Resistance-Associated Macrophage Protein 2 (NRAMP 2),
Divalent Cation Transporter-1 (DCT-1) or Solute Carrier Family 11 Member 2 (SCL11A2), is an
active divalent metal transporter found in all kingdoms of life, with a high degree of sequence
conservation1. In human, the expression of DMT-1 in duodenal enterocyte was first reported by
Gunshin et al., in 19972. They showed that DMT-1 can transport various divalent metals (Fe2+, 
Zn2+, Cd2+, Mn2+, Cu2+, Co2+, Ni2+, Pb2+), and is highly expressed in duodenum, followed by a
slightly lesser expression in kidney and a small amount of expression in brain. They also showed
the increase in DMT-1 expression in duodenum, in iron deficient diet. Following this discovery,
many studies have been conducted on DMT-1 to evaluate its structure and mechanism of metal
transport.
For an efficient absorption of non-heme iron from diet, the cooperative involvement of
both Dcytb and DMT-1 is required. Fe3+ iron from diet is first reduced by dcytb before being
transported into the duodenal enterocyte by DMT-1. The fe2+ is then captured by PCBP-2, carried 
to ferroportin, transported into the blood vessel, oxidized back to ferric by hephaestin, and carried 
to other parts of cells in transferrin bound form. A missing piece of information here, is how the
reduced Fe2+ is transported from Dcytb to DMT-1 (Figure 4-1). This information is important as
it determines the amount of iron absorbed from diet. In order to propose some hypothesis, the
structural properties of DMT-1 and Dcytb was studied in detail.
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Figure 4-1. Schematic representation of iron transport from gut lumen to the blood vessel.
The route of iron transport from gut lumen to blood vessel is well understood by regulatory role
of various proteins, which includes DMT-1, PCBP-2, Fpn-1 and Tf. However, the question on
how the reduced Fe2+ is transported from Dcytb to DMT-1 is yet to be solved.
4-1-1 Structural analysis of DMT-1
DMT-1 is generally known to have 12 transmembrane domains, and like Dcytb, both its
N- and C-terminal regions are placed on the cytoplasmic side. So far, two crystal structure of
DMT-1 have been reported. The first structure is from Staphylococcus capitis, was reported by
Ehrnstorfer et al., in 2014. In this report, they showed the metal binding site in DMT-1, and found
that the amino acids involved in the metal binding are conserved in human DMT-1. This binding
site is known to be conserved among all family members of DMT-1 regardless of species1. 
Consequently, this group reported another crystal structure of DMT-1 from Eremococcus
coleocola, in 2017. On contrary to the previously reported structure, the outward facing
conformation of DMT-1 was reported in this study. They showed proton-coupled transition metal
transport by DMT-1 using structural and functional study3. Based on these reported structures,
the metal binding side and the transport mechanism are probably conserved in human DMT-1.
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Indeed, sequence alignment between these three proteins showed that the bacterial DMT-1 shared 
30 to 37% identity to human DMT-1. However, a huge difference was observed from the 
sequence alignment, where the human DMT-1 has relatively long N- and C-terminal sequence 
(Figure 4-2). Since this feature is very specific to human, solving the structure of human DMT-1 
might give us new insights into this protein’s function. 
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Human YVRDLGHVALYVVAAVVSVAYLGFVFYLGWQCLIALGMSFLDCGHTCHLGLTAQPELYLL 
Staphylococcus ................. 
Eremococcus ................. 
Human NTMDADSLVSRLVPRGS 
Figure 4-2. Sequence alignment of DMT-1 from bacteria and human. DMT-1 from
Staphylococcus capitis, Eremococcus coleocola and human are aligned. Residues conserved in
all three sequences are highlighted in red. Human DMT-1 has a N- and C-terminal sequence that
is longer than bacterial DMT-1
The lengthy N- and C-terminal sequence of DMT-1 classify this protein into four isoforms,
that are characterized by two transcripts at both terminals (Figure 4-3). Two alternative transcripts
identified on the C-terminal, known as +IRE and -IRE, which means with and without iron
responsive element (IRE). IRE mediates controlled expression of DMT-1 under iron deficiency,
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by binding to iron regulatory proteins (IRPs). Another two additional transcripts were identified
on the N-terminal, one mRNA transcript starts in exon 1A, skips the next exon (1B), and splices
directly with exon 2, and another mRNA transcript, skips exon 1A, starts in exon 1B and splices
with exon 2.
Figure 4-3. Schematic representation of four DMT-1 isoform. DMT-1 consists of 12
transmembrane helices, with differing lengths of N- and C-terminals regions, that characterize
this protein into four isoforms. The N- and C- terminal region are expanded and the number of
amino acid residues are shown. As shown in the diagram, the N-terminal region of DMT-1 can 
either possess only exon 1B (blue) or both exon 1A (red) and 1B (blue). On the C-terminal end,
amino acid residues are conserved from 533 to 543, and differs in sequence and length thereafter
for DMT-1 with (purple) and without (green) the iron responsive element (IRE).
The exclusive N-terminal peptide sequence encoded by exon 1A contains extra 29 amino
acids on the upstream of 1B, that contains the signal sequence, Leu16, that has the role as a
retention signal for plasma membrane. In addition to these, this isoform contains 2 N-linked
glycosylation sites, N365 and N378, that play a critical role in targeting the protein to the apical
membrane4 (Figure 4-3). Based on these known properties, the four isoforms of human DMT-1 
are listed as follow, 1A/(+IRE), 1A/(−IRE), 1B/(+IRE), and 1B/(−IRE)5. Out of these four
isoforms, 1A/(+IRE) is tissue specific, and is highly expressed in duodenum and caco-2 cells.
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In addition to aiding in categorizing the isoforms, the cytoplasmic loop of DMT-1 plays a
crucial role in regulating the non-heme iron transport from gut lumen into duodenal enterocyte.
The Fe2+-transport is initiated only when the N-terminal region of DMT-1 interacts with PCBP-
2, a Fe2+ chaperone. Following that, there is possibility that this cytoplasmic loop is also involved 
in regulating the transport of reduced Fe2+ from Dcytb to DMT-1. In order to propose some
interaction site between Dcytb and DMT-1, the structural properties of Dcytb was analyzed in
detail.
4-1-2 Structural summary of Dcytb
The current structure of Dcytb provides extensive knowledge on the individual Fe3+
reduction function by Dcytb, in terms of the substrate binding and electron transfer. However,
around 56 amino acid residues at the C-terminal region are absent in this structure because the
electron density map was highly disordered. Some reports on single nucleotide polymorphisms
(SNPs) linked with hereditary hemochromatosis showed mutations of two amino acids residues,
R226H and S266N (Figure 4-4) around this C-terminal region6, 7. The position of these mutants
increase the curiosity about the role of this region in regulating iron absorption.
Figure 4-4. SNPs in Dcytb that are linked to hereditary hemochromatosis. Two amino acid
residues, R226 and S266, around the C-terminal region are mutated as a result of this
polymorphism.
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The possible role of this region in localization has already been discussed in section 3-4-1 
by comparison with other human cytochrome b561 family members. In addition to this, like DMT-
1, the cytoplasmic loop of Dcytb might also have regulatory role for controlled non-heme iron
absorption. For instance, this region may contain ubiquitination site like ferroportin-1.
Ferroportin-1 contains ubiquitination site on its cytoplasmic loop, which is the binding site of N-
terminal of hepcidin. When iron level is elevated in human body, this regulation system is
activated to prevent iron overload9. In addition to this, this cytoplasmic loop of Dcytb might also
interact with other related proteins like DMT-1 for the regulation of controlled non-heme iron
absorption from diet. This possibility will be further discussed in the next section.
4-1-3 Interaction between Dcytb and DMT-1 
A critical factor needed to initiate a substrate transfer from one protein to another is the
signal between two involved proteins. One way this signal is formed is via interaction between 
the respective proteins. For instance, Fe2+ transport from DMT-1 to PCBP-2 is induced by the
interaction between PCBP-2 and N-terminal of DMT-1, and Fe2+ transport from PCBP-2 to
ferroportin-1 is induced by the interaction between PCBP-2 and C-terminal of ferroportin-1.
Similarly, Fe2+ transport from Dcytb to DMT-1 probably mediated by the interaction between 
these two proteins (Figure 4-5). However, an interesting issue is where does the interaction
occurs. Both previous examples show interaction between soluble protein and membrane protein.
However, Dcytb and DMT-1 are both membrane proteins and to date there is no significant
evidence to prove or disprove the complex of these two proteins. Interaction might occur either
directly between the C-terminal of Dcytb and N-terminal of DMT-1, or indirectly mediated by
the known interacting protein, PCBP-2. In order to test this hypothesis the structural properties of
DMT-1 with and without PCBP-2 need to be studied.
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4-1-4 Existence of a Fe2+-chelator in the gut lumen
Structural studies of Dcytb also revealed an important role of dietary iron chelators in
transporting Fe3+ to the binding pocket on the apical surface of Dcytb. This finding shows that
free iron in our body always requires chelator or carrier to be transported elsewhere. For instance,
Fe2+ in duodenal cytoplasm is chelated by PCBP-2 and Fe3+ in blood plasma is carried by 
transferrin. However, to date, there’s no information available on the existence of Fe2+ chelator
in the lumen of duodenum. One possibility is that, after Fe3+ reduction by Dcytb, Fe2+ is
continuously chelated by ascorbate to prevent Fe2+ oxidation10, and is carried to DMT-1. Upon
binding of Fe2+-ascorbate complex to DMT-1, Fe2+ is released and transported into duodenal
enterocyte. This hypothesis can be tested by functional studies to check affinity between ascorbate
and DMT-1, or by structural studies by solving the complex structure of DMT-1 with Fe2+-
ascorbate, to check if there is any possible binding site.
The two proposed options that might be responsible for the transfer of the reduced Fe2+ 
from Dcytb and DMT-1 are summarized in Figure 4-5.
Figure 4-5. Schematic representation of iron transport from gut lumen to the blood vessel. 
Fe2+ reduced by Dcytb is carried to DMT-1 by either or both Fe2+ chelator and possible interaction
between Dcytb and DMT-1.
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Clearly, more research is needed to test both these hypotheses. As an initial approach to that, the
structural and functional properties of DMT-1 is currently being studied. The objective of my
future plans is to understand the structural feature of 1A/(+IRE) isoform. This isoform contains
the signal sequence on its N-terminal that interact with iron chaperone PCBP2 for subcellular
distribution of Fe2+, and also probably contains the signal sequence that interact with Dcytb to
trigger or terminate the Fe2+ transport from gut lumen into duodenal enterocyte. Following that,
the proposed experiments are as follow:
1) Establish the expression and purification protocol for 1A/(+IRE) DMT-1 isoform.
2) Crystallization of DMT-1 by vapor diffusion and LCP techniques.
3) Co-crystallization of DMT-1 with the known interacting protein, PCBP-2, to see the
protein interacting side. Probably the interacting side of DMT-1 to Dcytb is the same
as PCBP2. In that case, this information could be used for site directed mutagenesis
studies and in vivo functional assay.
This coming research will provide understanding about the structural and functional features of
1A/(+IRE) DMT-1 isoform, which can provide answers to many unsolved questions on controlled
iron absorption in human.
4-2 Preliminary purification of DMT-1
4-2-1 Material and methods
4-2-1-1 Expression of DMT-1
Artificially synthesized (Biomatik), codon optimized human DMT-1 gene (isoform
1A/(+IRE)) that includes C-terminal His-tag was cloned into pPIC9K vector (Invitrogen) for
expression in Pichia pastoris. Preculture was grown in 5 mL BMGY medium overnight at 30°C
with constant stirring at 180 rpm. Cells harvested from preculture was washed and resuspended 
with 5 mL of sterilized water. This cell was used for the main culture (75 mL of BMY medium
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containing 1% (w/v) yeast extract, 2% (w/v) peptone, 0.1 M potassium phosphate buffer, 1.34%
(w/v) yeast nitrogen base, 0.002% (w/v) biotin and 0.5% methanol) to a final OD600 of 0.5. The
cells were grown at 30°C with constant stirring at 180 rpm for 24 hours. The culture was
supplemented with another 0.5% methanol, further grown for 6 more hours and harvested. The
harvested cells (~ 4 g) were resuspended in 40 mL lysis buffer containing 50 mM potassium
phosphate buffer (pH 7.6), 150 mM NaCl and one tablet of cOmplete EDTA-free protease
inhibitor cocktail (Roche), followed by disruption by vortexing with zirconia beads (equal volume
with lysis buffer) for 8 min ((1 min disruption +5 min interval on ice) – repeat 8 times). Cell
debris was removed by centrifugation (10,000 × g for 20 min). The supernatant fluid was collected
and sedimented by ultracentrifugation (40,000 × g for 1 h) to obtain the membrane fraction.
Membrane fraction was then homogenized with lysis buffer.
4-2-1-2 Purification of DMT-1
The membrane fraction (~ 0.25 g) was homogenized in solubilization buffer (Na2HPO4 (50 mM),
citric acid (10 mM) and NaCl (150 mM), pH 5.8). The membrane concentration was measured 
by bicinchoninic acid assay (BCA assay), and final concentration of membrane was adjusted ~7
mg/mL before solubilization of the membrane with 1% (w/v) DDM for 1 h at 4°C. Following
ultracentrifugation (40,000 rpm for 1 h), the supernatant fluid was loaded onto a column of Ni2+-
nitrilotriacetate affinity resin (Ni-NTA; Qiagen). Non-specifically bound material was eluted
from this column with lysis buffer containing 10 mM imidazole (pH 5.8) (washing buffer), and
the solubilized DMT-1 was eluted by stepwise elution using the same buffer containing 100, 300
and 500 mM imidazole (pH 5.8).
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4-2-2 Results
4-2-2-1 Purification of DMT-1 
Recombinant human DMT-1 was overexpressed in Pichia pastoris and purified by
nickel-affinity (Figure 4-6). DMT-1 can be successfully purified by affinity chromatography,
However, based on the SDS-PAGE analysis, high purity is not achieved by this single step
purification. Further optimization to obtain protein with high purity for crystallization trials will
be performed in near future. As an initial approach, the protein purity will be improved by gel
filtration chromatography.
Figure 4-6. Preliminary purification profile of DMT-1. DMT-1 was purified by affinity
chromatography using Ni-NTA column. The protein was eluted by stepwise elution using 100,
300 and 500 mM imidazole.
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Chapter 5: General conclusion
Deficiency or over exposure to iron has been known to cause noticeable effects to human.
Studies are being continuously conducted to understand the role of various proteins involved in
maintaining the complex iron homeostasis in human, to find solutions to this extensively
spreading iron imbalance diseases. In the current study, attempt was made to explain the role of
three important membrane proteins, CeHRG-4, Dcytb and DMT-1, involved in the regulation of
systemic iron homeostasis.
In the first part of this study (Figure 5-1), the role of heme transport by CeHRG-4 has been 
functionally proved. However, the transport mechanism remains unsolved due to the challenges
in crystallization and atomic level structural determination. Crystallization of CeHRG-4 by LCP
technique to provide a native like environment for the crystal packing is the nearest future plan
that can be performed for this project.
Heme Protoporphyrin IX 
C 
N 
Atomic structure ?? 
Mechanism ?? 
LCP crystallization to improve crystal packing 
Figure 5-1. Summary of CeHRG-4 study. The role of CeHRG-4 in the transport heme and
porphyrin ring is known from functional assay. However, the mechanism of heme transport
remains unsolved due to the challenges in crystallization.
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In the second part of this study, the role of Dcytb and DMT-1 in non-heme iron absorption 
was studied. This study summarizes some important structural aspects of Dcytb, in terms of
substrate binding and electron transfer route. This is the first reported structure that shows the
metal binding site for a cytochrome b561 family member. This is also the first structure that
emphasize the importance of chelators in increasing Fe3+ solubility and binding stability, which
in turn enhances the ferric reductase activity. Nevertheless, the C-terminal end loop region could
not be modelled in the current structure (Figure 5-2). Based on some reported polymorphisms in
Dcytb, this region is probably involved in the regulatory role of iron absorption to control iron
related diseases like iron overload. The study to analyse the possible role of this C-terminal region
in iron regulation through interaction with other related proteins like DMT-1 is currently on-going.
This hopefully provides a better understanding to address iron related diseases like iron deficiency 
anemia and hereditary hemochromatosis.
Figure 5-2. Summary of structural analysis of Dcytb. The current structure provides
information on the mechanism of Fe3+ reduction by Dcytb and the importance of dietary iron
chelators in mediating Fe3+ reduction.
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